+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04404088

Study of Acalabrutinib, Lenalidomide, and Rituximab in Previously Untreated Follicular Lymphoma Patients

Led by M.D. Anderson Cancer Center · Updated on 2026-11-02

80

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of acalabrutinib, lenalidomide, and rituximab in treating patients with previously untreated CD20 positive stage III-IV, grade 1-3a follicular lymphoma. This phase II trial aims to assess how well these drugs work together to control the disease, focusing on complete remission and other response measures, while also studying safety, tolerability, and biological effects. Participants receive acalabrutinib orally twice daily for 28 days in the first cycle. From the second cycle onward, lenalidomide is taken orally once daily for 21 days, and rituximab is given intravenously on days 1, 8, 15, and 22 of cycle 2 and day 1 of subsequent cycles. Treatment cycles repeat every 28 days for a total of 13 cycles unless the disease progresses or side effects become unacceptable. During the study, participants undergo regular monitoring including assessments of disease response, side effects, and biomarker studies. After completing treatment, follow-up visits occur every 3 months for one year and then every 6 months for two more years to evaluate long-term outcomes such as progression-free survival and overall survival. Researchers will also track treatment-related adverse events throughout the study period.

CONDITIONS

Brief Title

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Research Team

P

Paolo Strati

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here